From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

Last Updated: Tuesday, June 17, 2025

Researchers evaluated the 12-year outcomes of the C9741 trial to identify patients most likely to benefit from dose-dense chemotherapy. They found that low endocrine activity in the cancer was a predictor of benefit.

Journal of Clinical Oncology
Advertisement
News & Literature Highlights
Advertisement
Advertisement